Imipramine Reverses Sorafenib Resistance in Hepatocellular Carcinoma by Targeting the BLOC1S5/FOXO1 Signaling Axis

Biomedical Journal · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles